Drug Approval | February 18, 2023
Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
Themis will market this drug with the brand name REMITHEM.
Themis will market this drug with the brand name REMITHEM.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
To focus on providing safer burn treatments for women and armed forces
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Company hires life science veteran Jessica Cao to join management team
Subscribe To Our Newsletter & Stay Updated
